GP 1626

#

COVINGTON & BURLING

1201 PENNSYLVANIA AVENUE NW WASHINGTON, DC 20004-2401 TEL 202.662.6000 FAX 202.662.6291 WWW.COV.COM WASHINGTON NEW YORK LONDON BRUSSELS SAN FRANCISCO ANDRÉA G. REISTER
TEL 202.662.5141
FAX 202.778.5141
AREISTER @ COV.COM
November 9, 2000

NOV 1627000

Commissioner for Patents Washington, D.C. 20231

Re:

U.S. Utility Patent Application

Appl. No.: 09/578,908; Filed: May 26, 2000

For: Microencapsulated 3-Piperidinyl-Substituted

1,2-Benzisoxazoles and 1,2-Benzisothiazoles

Inventors:

Mesens et al.

Our Ref: 001

00166.0051.US05

APR 1 6 2001
TECH CENTER 1600/2900

Sir:

Transmitted herewith for appropriate action by the U.S. Patent and Trademark Office (PTO) are the following documents:

- 1. Form PTO-1083 (in duplicate);
- 2. Second Preliminary Amendment; and
- 3. Return receipt postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 50-0740 referencing docket number 00166.0051.US05. A duplicate copy of this letter is enclosed.


Respectfully submitted

Andrea G. Reister (Reg. No. 36,253)

Enclosures

B





(202) 662-6000

FORM PTO-1083

In re application of Mesens et al. Appl. No. 09/578,908

Filed: May 26, 2000

For: Microencapsulated 3-Piperidinyl-Substituted

1,2-Benzisoxazoles and 1,2-Benzisothiazoles

THE COMMISSIONER FOR PATENTS Washington, D.C. 20231

Sir:

Transmitted herewith is an amendment in the above-identified application.

- Small entity status of this application under 37 CFR §§ 1.9 and 1.27 has been established by a statement previously submitted.
- A statement to establish small entity status under 37 CFR §§ 1.9 and 1.27 is enclosed.
- No additional claim fee is required.

The claim fee has been calculated as shown below:

	(Col. 1)		(Col. 2)	(Col. 3)			
	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra			
Total Claims	* 28	MINUS	** 20	= 8			
Indep. Claims	* 5	MINUS	** 3	= 2			
☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM							

Rate	Addit. Fee		
x 9=	\$	00.00	
x 39 =	\$	00.00	

\$ 00.00

Total \$ 00.00 Addit. Fee

+130

OTHER THAN A **SMALL ENTITY**

TECH CENTER 1600/2900

Attorney Do

DIVINION DIVITI				
Rate	Addit. Fee			
x 18 =	\$	144.00		
x 80 =	\$	160.00		
+ 260 =	\$	00.00		
TOTAL	\$	304.00		
	Rate x 18 = x 80 = + 260 =	Rate x 18 = \$ x 80 = \$ + 260 = \$		

- If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
- If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.
- *** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space. The "Highest Number Previously Paid For" (Total or Independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment or the number of claims originally filed.
- Please charge my Deposit Account No. 50-0740 in the amount of \$304.00 referencing docket number 00166.0051.US05. A \underline{XX} duplicate copy of this sheet is attached.
- Check number * in the amount of \$_*.00 is attached.
- The U.S. Patent and Trademark Office is hereby authorized to charge payment of the following fees associated with this \underline{XX} communication or credit any overpayment to Deposit Account No. __50-0740_ referencing docket number *. A duplicate copy of this sheet is attached.
 - Any filing fees under 37 CFR § 1.16 for the presentation of extra claims. XX
 - Any patent application processing fees under 37 CFR § 1.17. \underline{XX}

Date: November 9, 2000